AZ’s Imfinzi is first immunotherapy to raise survival in biliary tract cancer

AZ’s Imfinzi is first immunotherapy to raise survival in biliary tract cancer

Source: 
Pharmaforum
snippet: 

AstraZeneca’s checkpoint inhibitor Imfinzi has become the first cancer immunotherapy to improve survival in previously-untreated patients with biliary tract cancer (BTC), a rare and aggressive group of gastro-intestinal tumours.